Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species

New Microbiologica

Volumn 31, Issue 2, 2008, Pages 257-262

  Serefko, Anna ^a   Los, Renata ^a   Biernasiuk, Anna ^a   Malm, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Broth microdilution method; Candida non albicans; Caspofungin; E test

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN;

ADULT; ARTICLE; CANDIDA; CANDIDIASIS; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA;

EID: 46649099895     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. BARRY A.L., PFALLER M.A., BROWN S.D., ESPINEL-INGROFF A., GHANNOUM M.A., KNAPP C., RENNIE R.P., REX J.H., RINALDI M.G. (2000). Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38, 3457-3459.
2. BARTIZAL C., ODDS EC. (2003). Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47, 2100-2107.
3. CHRYSSANTHOU E., CUENCA-ESTRELLA M. (2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40, 3841-3844.
4. CYBULSKI Z., KRZEMINSKA-JASKOWIAK E., GRABIEC A., TALAGA Z. (2003). The comparison of antifungal susceptibility of C. glabrata, C. tropicalis, C. parapsilosis, C. krusei and C. kefyr isolated from different sources [in Polish]. Wspol. Onkol 7, 404-409.
5. ESPINEL-INGROFF A. (1998). Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36, 2950-2956.
6. KUHN D.M., GEORGE T., CHANDRA J., MUKHERJEE P.K., GHANNOUM M.A. (2002). Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46, 1773-1780.
7. LAVERDIERE M., RESTTERI C., HABEL F. (2002). Evaluation of the in vitro activity of caspofungin against blood-stream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference method. Int. J. Antimicrob. Agents. 20, 468-471.
8. LETSCHER-BRU V., HERBRECHT R. (2003). Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. 51, 513-521.
9. MARCO F., PFALLER M.A., MESSER S.A., JONES R.N. (1998). Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida sp. Diagn. Microbiol. Infect. Dis. 31, 33-37.
10. MAJOROS L., KAROOS G., SZABÓ B., SIPICZKI M. (2005). Caspofungin susceptibility testing Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Antimicrob. Agents Chemother. 49, 3486-3488.
11. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. (1997). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. OSTROSKY-ZEICHNER L., REX J.H., PAPPAS P.G., HAMILL R.J., LARSEN R.A., HOROWITZ H.W., POWDERLY W.G., HYSLOP N., KAUFFMAN C.A., CLEARY J., MANGINO J.E., LEE J. (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47, 3149-3154.
13. PFALLER M.A., JONES R.N., DOERN G.V., FLUIT A.C., VERHOEF J., SADER H.S., MESSER S.A., HOUSTON A., COFFMAN S., HOLLIS R.J. (1999a). International surveillance of blood stream infections due to Candida species in the European Sentry Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35, 19-25.
14. PFALLER M.A., MESSER S.A., BOYKEN L., RICE C., TENDOLKAR S., HOLLIS R.J., DIEKEMA D.J. (2004). Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42, 3117-3119.
15. PFALLER M.A., MESSER S.A., GEE S., JOLY S., PUJOL C., SULLIVAN D.J., COLEMAN D.C., SOLL D.R. (1999b). In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37, 870-872.
16. PFALLER M.A., MESSER S.A., MILLS K., BOLMSTRÖM A., JONES R.N. (2001). Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. 39, 4387-4389.
17. SEREFKO A., CHUDZIK B., MALM A. (2006). In vitro activity of caspofungin against planktonic and sessile Candida sp. cells. Pol. J. Microbiol. 55, 133-137.
18. STEVENS D.A., ESPIRITU M., PARMAR R. (2004). Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48, 3407-3411.
19. ULLMANN A.J. (2003). Review of the safety, tolerability and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 19, 263-271.